Abstract
Purpose
In recent years, water vapor thermal therapy (WVTT) has spread as minimally invasive technique in lower urinary tract symptoms due to benign prostatic hyperplasia treatment. Even if its safety and feasibility have been largely proved in young men, nobody has proved the same feasibility and safety in the elderly (men older than 75 years old). Our aim is to compare WVTT safety outcomes in men older than 75 with younger men.
Methods
We prospectively collected data on men who underwent water vapor thermal therapy from 2019. We compared data on operative time, number of injections, intra-operative and post-operative complications, reinterventions rate.
Results
We enrolled 426 patients; among these, 60 were older than 75 years old, 366 were younger. Our cohorts of patients had similar results in terms of intra-operative and post-operative complications. Operative time accounts about 11 min for both groups (p = 0.535), total number of injections was seven for young men and eight for elderly (p = 0.314). We found no intra-operative complications in elderly men group and only one in the younger group (p = 0.678), while five younger men underwent clot retention, and two elderly men experienced this complication (p = 0.239). Only one transfusion occurred in the elderly group. No differences between groups occurred in terms of length of stay, post-operative urinary retention and reintervention rate, while catheterization time was longer in the elderly men.
Conclusion
WVTT is a safe procedure in elderly patients with comparable intra-operative and post-operative complication rate in comparison with younger patients.
Similar content being viewed by others
Data availability
The raw data are available upon reasonable and motivated request.
References
Ng M, Baradhi KM (2023) Benign prostatic hyperplasia. StatPearls. StatPearls Publishing, Treasure Island
Ornaghi PI, Porreca A, Sandri M et al (2022) Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases. Prostate Cancer Prostat Dis. https://doi.org/10.1038/s41391-022-00575-w3
Cindolo L, Pirozzi L, Fanizza C et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68:418–425. https://doi.org/10.1016/j.eururo.2014.11.006
McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803. https://doi.org/10.1016/j.juro.2011.01.074
Manfredi C, Arcaniolo D, Spatafora P et al (2022) Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol. https://doi.org/10.23736/S2724-6051.21.04530-4
Woo HH, Huang CP, Huang WJ et al (2022) The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Prostate Cancer Prostat Dis 25:576–582. https://doi.org/10.1038/s41391-022-00548-z6
Kaplan SA, Pichardo M, Rijo E et al (2021) One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer Prostat Dis 24:1073–1079. https://doi.org/10.1038/s41391-021-00362-z
Siena G, Cindolo L, Ferrari G et al (2021) Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol 39:3875–3880. https://doi.org/10.1007/s00345-021-03642-4
Siena G, Tellini R, Cindolo L (2022) Can Rezum stand out as the most versatile and better performing minimally invasive treatment for the management of LUTS related to BPH? Minerva Urol Nephrol. https://doi.org/10.23736/S2724-6051.22.04861-3
Campobasso D, Siena G, Chiodini P et al (2023) Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study. Prostate Cancer Prostat Dis 26:410–414. https://doi.org/10.1038/s41391-022-00587-6
Khan KT, Hemati K, Donovan AL (2019) Geriatric physiology and the frailty syndrome. Anesthesiol Clin 37:453–474. https://doi.org/10.1016/j.anclin.2019.04.006
Campobasso D, Morselli S, Greco F et al (2023) Efficacy and safety profile of GreenLight laser photoselective vaporization of the prostate in ≥ 75 years old patients: results from the Italian GreenLight Laser Study Group. Aging Clin Exp Res 35:877–885. https://doi.org/10.1007/s40520-023-02351-9
Cindolo L, Campobasso D, Ferrari G et al (2022) Expanding indications for Rezum procedure. Urol Video J 14:100154. https://doi.org/10.1016/j.urolvj.2022.100154
Vuichoud C, Loughlin KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(Suppl 1):1–6
Huang J, Chan C-K, Yee S et al (2023) Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer Prostat Dis 26:421–428. https://doi.org/10.1038/s41391-022-00610-w
Albisinni S, Aoun F, Roumeguère T et al (2017) New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nephrol. https://doi.org/10.23736/S0393-2249.16.02743-0
McVary KT, Rogers T, Mahon J, Gupta NK (2018) Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med 15:1728–1738. https://doi.org/10.1016/j.jsxm.2018.10.006
Sahakyan Y, Erman A, Bhojani N et al (2023) Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. Prostate Cancer Prostat Dis 26:113–118. https://doi.org/10.1038/s41391-022-00561-2
Elterman D, Bhojani N, Vannabouathong C et al (2022) Rezūm therapy for ≥80- mL benign prostatic enlargement: a large, multicentre cohort study. BJU Int 130:522–527. https://doi.org/10.1111/bju.15753
Spinos T, Katafigiotis I, Leotsakos I, Grivas N, Zabaftis C, Ermidis D, Sfoungaristos S, Karavitakis M (2023) Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature. World J Urol 41(2):413–420. https://doi.org/10.1007/s00345-022-04258-y
Babar M, Labagnara K, Loloi J et al (2023) Risk factors and real-world short-term outcomes of a failed trial of void after rezum therapy in a multiethnic population. J Endourol 37:67–73. https://doi.org/10.1089/end.2022.0490
Tadrist A, Baboudjian M, Bah MB et al (2022) Water vapor thermal therapy for indwelling urinary catheter removal in frail patients. Int Urol Nephrol 55:249–253. https://doi.org/10.1007/s11255-022-03408-w
Cornu J-N, Ahyai S, Bachmann A et al (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67:1066–1096. https://doi.org/10.1016/j.eururo.2014.06.017
Nishi T, Maeda T, Imatoh T, Babazono A (2018) Comparison of regional with general anesthesia on mortality and perioperative length of stay in older patients after hip fracture surgery. Int J Qual Health Care. https://doi.org/10.1093/intqhc/mzy233
Siena G, Sessa F, Cindolo L (2023) Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate. Prostate Cancer Prostat Dis. https://doi.org/10.1038/s41391-023-00644-8
Elterman DS, Zorn KC, Bhojani N, Chughtai B (2022) Efficacy and safety of methoxyflurane (Penthrox) for pain control during water vapor thermal therapy (Rezum) for benign prostatic enlargement. Can J Urol 29:11355–11360
Author information
Authors and Affiliations
Contributions
AM: data collection, manuscript writing. SM: data analysis, manuscript writing. FF: data collection. DM: data collection. FV: data collection. ST: data collection. GF: project development. GS: project development, data collection. EC: data collection. RP: project development. FU: project development. Balsamo R: project development, data collection. RMS: project development, manuscript supervision. LC: project development, data analysis, manuscript supervision.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial interests and no other conflict of interests to disclose.
Research involving human and animal participants
The research involves human participants but not animals.
Ethical approval
To proceed with the study, ethical appraisal was obtained for the current study (Ref AOC-0020489-2022). Data sharing between centers was conducted according to EU privacy regulations, with anonymized data to safeguard patients’ privacy.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Minore, A., Morselli, S., Franzoso, F. et al. Is water vapor thermal therapy safe and feasible in elderly and frail men? The Italian experience. World J Urol 42, 60 (2024). https://doi.org/10.1007/s00345-023-04762-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00345-023-04762-9